Startup profile · funding coverage
MiRus funding, valuation and investors
Marietta medtech company commercializing MoRe molybdenum-rhenium alloy implants for spine, orthopedics, and TAVR.
Keep track of MiRus
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Strategic investment
$1.5B · May 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$1.5B
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
growth · Marietta, Georgia, USA
Investors in latest funding
Lead: Boston Scientific
Overview
MiRus LLC, founded in 2015 and headquartered in Marietta, Georgia, develops and commercializes proprietary molybdenum-rhenium (MoRe) biomaterial implants and procedural solutions for spine, orthopedic, and structural heart disease. The MoRe alloy offers higher strength and fatigue resistance than titanium or cobalt-chromium, enabling smaller, more durable implants with a lifetime limited warranty on spinal rods. Commercial spine products include the EUROPA pedicle screw system and Cygnus anterior cervical plating. In cardiovascular, MiRus is developing the SIEGEL balloon-expandable TAVR valve — described as the first nickel-free balloon-expandable TAVR — with encouraging U.S. Early Feasibility Study 30-day results presented at NY Valves 2025. In May 2026, Boston Scientific invested $1.5 billion for approximately 34% equity and an exclusive option to acquire the TAVR business for up to $3 billion upon clinical milestones.
Why MiRus is interesting
MiRus' proprietary MoRe superalloy — inspired by NASA rocket-engine materials science — enables thinner, stronger, nickel-free implants with lower metal-ion release; Boston Scientific's $1.5B strategic stake signals conviction in its SIEGEL TAVR program.
Product & use cases
MiRus manufactures FDA-cleared spine and orthopedic implants from proprietary MoRe molybdenum-rhenium superalloy, plus a developing SIEGEL TAVR valve platform — integrated pre-operative planning, navigation, and post-operative monitoring across the care continuum.
- Posterior and anterior cervical spinal fusion with MoRe rods and pedicle screw systems
- Structural heart: transcatheter aortic valve replacement via SIEGEL low-profile delivery system
- Orthopedic implants requiring higher strength-to-size ratio and reduced metal-ion exposure
- Complex spinal deformity cases where rod fracture rates drive costly revision surgeries
Key facts
- Boston Scientific strategic investment (May 2026): $1.5B for ~34% equity stake — SEC filing, PR Newswire
- Exclusive option for BSX to acquire TAVR business for additional $3B upon clinical/regulatory milestones
- SIEGEL TAVR U.S. EFS: 15 patients, zero deaths/strokes/re-hospitalizations at 30 days (PR Newswire, July 2025)
- MoRe alloy backed by 15+ years R&D — lifetime limited warranty on MoRe spinal rods since 2021
- Spine products include EUROPA pedicle screw system with NTAP add-on payment (CMS)
- Founded by experienced medtech entrepreneurs; MoRe materials inspired by NASA rocket-engine alloy work
Funding history (newest first)
Strategic investment
2026-05 $1.5B- Boston Scientific (lead)
Competitive landscape
Edge: Proprietary MoRe alloy enables thinner-walled, nickel-free implants with superior fatigue resistance and radiopacity — differentiated from titanium and cobalt-chromium incumbents, especially in TAVR hemodynamics.
Medtech megarounds are rare outside AI, but MiRus' $1.5B Boston Scientific deal reflects validated materials science plus a credible TAVR path. Spine revenue provides commercial base while SIEGEL EFS data de-risks the cardiovascular upside — execution on pivotal trials determines whether BSX exercises its $3B acquisition option.
-
Medtronic incumbent
Global spine and TAVR leader (Evolut, CoreValve); MiRus targets differentiation via MoRe alloy and nickel-free SIEGEL design.
-
Edwards Lifesciences incumbent
Dominant TAVR franchise (SAPIEN); MiRus SIEGEL aims for low delivery profile and strong hemodynamics via rhenium alloy frame.
-
Stryker incumbent
Major spine implant portfolio; MiRus competes on MoRe rod durability and lifetime warranty versus conventional titanium systems.
-
Zimmer Biomet incumbent
Broad orthopedic and spine offerings; MiRus differentiates on proprietary alloy science rather than scale.
Notable stories
- MiRus MoRe alloy work traces to NASA rocket-engine refractory metals research — the same molybdenum-rhenium chemistry now used for body-temperature medical implants (MiRus technology page, IMOA industry publication).
- Boston Scientific's $1.5B stake is its third swing at the TAVR market — MiRus' nickel-free SIEGEL valve gives BSX an exclusive option worth up to $3B more if clinical milestones hit (MD+DI, May 2026).
Industries
Market / IPO context
Editorial / static context — not a live quote.
Related funding articles
Venture Capital Tracker pieces that cover MiRus's financing or category context.
FAQs about MiRus
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.